IP Library Granted Patent US 11,124,552
Granted Patent B2
US 11,124,552 · App. 16/169,215 · Granted Sep 21, 2021

Compositions of phosphorylated tau peptides and uses thereof

Inventors: Elizabeth Anne Ramsburg (Chalfont, PA); Donata De Marco (Turnhout, BE); Charlotte Sadaka (San Diego, CA); Jaap Goudsmit (Amsterdam, NL); Andreas Muhs (Cugy, CH); Maria Pihlgren Bosch (Mont-sur-Lausanne, CH); Marija Vukicevic Verhille (St-Sulpice, CH); Nicolas Piot (Grandvaux, CH); Saroj Raj Ghimire (Chavannes-pres-Renens, CH)
Assignees: AC Immune SA; Janssen Pharmaceuticals, Inc.
C07K14/4711A61K9/127A61K9/1271A61K38/1709A61K39/0007A61K39/39A61P25/28A61K2039/55516A61K2039/55555A61K2039/55561A61K2039/55572A61K2039/6018A61K2039/627
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,124,552
App. No.
16/169,215
Granted
Sep 21, 2021
Kind
B2
Abstract

Liposomes containing tau peptides, preferably phosphorylated tau peptides, and conjugates containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier are described. Pharmaceutical compositions and uses of the liposomes and/or conjugates for treating or preventing a neurodegenerative disease or disorder, such as Alzheimer's Disease, are also described.

Claims (36)

1. A liposome, comprising:

a. a tau peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 5, 9, and 12;

b. a helper T cell epitope comprising at least one amino acid sequence selected from the group consisting of: SEQ ID NOs:23, 24, 25, and 26;

c. a lipidated CpG oligonucleotide having the nucleotide sequence of SEQ ID NO:18, wherein the CpG oligonucleotide comprises one or more phosphorothioate internucleotide linkages, and wherein the CpG oligonucleotide is covalently linked to at least one cholesterol via a linker; and

d. monophosphoryl lipid A (MPLA),

wherein the tau peptide is presented on the surface of the liposome.

2. The liposome of claim 1 , wherein:

a. the tau peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 28, 31, 35, and 38;

b. the lipidated CpG oligonucleotide has the nucleotide sequence of SEQ ID NO:18; and

c. the helper T cell epitope comprises the amino acid sequences of SEQ ID NO: 23, SEQ ID NO:24 and SEQ ID NO:25, wherein the amino acid sequences are covalently linked together, optionally via one or more linkers.

3. The liposome of claim 2 , wherein the helper T cell epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:39, 40, 41, 42, and 43.

4. The liposome of claim 2 , wherein the helper T cell epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:13, 14, 15, 16, 17, and 44.

5. The liposome of claim 1 , further comprising one or more lipids selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-sn-glycero-3-phosphoryl-3′-rac-glycerol (DMPG), and cholesterol.

6. A liposome, comprising:

a. a tau peptide comprising the amino acid sequence of SEQ ID NO: 2;

b. a helper T cell epitope having an amino acid sequence selected from the group consisting of SEQ ID NOs:39, 40, 41, 42, and 43;

c. a lipidated CpG oligonucleotide having the nucleotide sequence of SEQ ID NO:18, wherein the CpG oligonucleotide is covalently linked to at least one cholesterol via a linker; and

d. monophosphoryl lipid A (MPLA);

wherein the tau peptide is presented on the surface of the liposome.

7. The liposome of claim 6 , further comprising one or more lipids selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-sn-glycero-3-phosphoryl-3′-rac-glycerol (DMPG), and cholesterol, wherein:

a. the tau peptide has the amino acid sequence of SEQ ID NO:28;

b. the helper T cell epitope has the amino acid sequence of SEQ ID NO:39; and

c. the lipidated CpG oligonucleotide has the nucleotide sequence of SEQ ID NO:18.

8. The liposome of claim 7 , wherein the helper T cell epitope has the amino acid sequence of SEQ ID NO:13.

9. The liposome of claim 6 , further comprising one or more lipids selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-sn-glycero-3-phosphoryl-3′-rac-glycerol (DMPG), and cholesterol, wherein:

a. the tau peptide has the amino acid sequence of SEQ ID NO:28;

b. the helper T cell epitope has the amino acid sequence of SEQ ID NO:40; and

c. the lipidated CpG oligonucleotide has the nucleotide sequence of SEQ ID NO:18.

10. The liposome of claim 9 , wherein the helper T cell epitope has the amino acid sequence of SEQ ID NO:14.

11. The liposome of claim 6 , further comprising one or more lipids selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-sn-glycero-3-phosphoryl-3′-rac-glycerol (DMPG), and cholesterol, wherein:

a. the tau peptide has the amino acid sequence of SEQ ID NO:28;

b. the helper T cell epitope has the amino acid sequence of SEQ ID NO:41; and

c. the lipidated CpG oligonucleotide has the nucleotide sequence of SEQ ID NO:18.

12. The liposome of claim 11 , wherein the helper T cell epitope has the amino acid sequence of SEQ ID NO:15.

13. A pharmaceutical composition comprising the liposome of claim 6 and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising the liposome of claim 1 and a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2019
From: PIHLGREN BOSCH, MARIA; VUKICEVIC VERHILLE, MARIJA; HICKMAN, DAVID; PIOT, NICOLAS; GHIMIRE, SAROJ RAJ
To: AC IMMUNE S.A.
Reel/Frame 048847/0178 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2019
From: RAMSBURG, ELIZABETH ANNE; DE MARCO, DONATA; CHAKKUMKAL, ANISH; SADAKA, CHARLOTTE; GOUDSMIT, JAAP
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 048847/0603 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2019
From: MUHS, ANDREAS
To: AC IMMUNE S.A.
Reel/Frame 048976/0417 →
Continuity (2)
Provisional Application 62577157 · Oct 25, 2017
Related Publication 20190119341A1 · Apr 25, 2019
Cited By (2)
US 12,324,855 US 12,365,724